{{author}}{{author}}{{($index < metadata.AuthorsAndEtalArray.length-1) ? ',' : '.'}}

Galina Velikova, Kate Absolom, Jenny Hewison, Patricia Holch, Lorraine Warrington, Kerry Avery, Hollie Richards, Jane Blazeby, Bryony Dawkins, Claire Hulme, Robert Carter, Liz Glidewell, Ann Henry, Kevin Franks, Geoff Hall, Susan Davidson, Karen Henry, Carolyn Morris, Mark Conner, Lucy McParland, Katrina Walker, Eleanor Hudson & Julia Brown.

Galina Velikova ^1,2,*, Kate Absolom ^1,3, Jenny Hewison ³, Patricia Holch ^1,4, Lorraine Warrington ¹, Kerry Avery ⁵, Hollie Richards ⁵, Jane Blazeby ⁵, Bryony Dawkins ³, Claire Hulme ⁶, Robert Carter ¹, Liz Glidewell ⁷, Ann Henry ^1,2, Kevin Franks ^1,2, Geoff Hall ^1,2, Susan Davidson ⁸, Karen Henry ², Carolyn Morris ⁹, Mark Conner ¹⁰, Lucy McParland ¹¹, Katrina Walker ¹¹, Eleanor Hudson ¹¹, Julia Brown ¹¹

¹ Leeds Institute of Medical Research at St James’s, University of Leeds, Leeds, UK
² Leeds Teaching Hospitals NHS Trust, Leeds, UK
³ Leeds Institute of Health Sciences, University of Leeds, Leeds, UK
⁴ Psychology Group, School of Social Sciences, Leeds Beckett University, Leeds, UK
⁵ Bristol Centre for Surgical Research, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
⁶ Health Economics Group, Institute of Health Research, University of Exeter, Exeter, UK
⁷ Department of Health Sciences, University of York, York, UK
⁸ The Christie NHS Foundation Trust, Manchester, UK
⁹ Independent Cancer Patients’ Voice, London, UK
¹⁰ School of Psychology, University of Leeds, Leeds, UK
¹¹ Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK
^* Corresponding author Email: g.velikova@leeds.ac.uk

Declared competing interests of authors: Galina Velikova reports personal fees from Roche Holding AG (Basel, Switzerland), Eisai Co., Ltd (Tokyo, Japan) and Novartis International AG (Basel, Switzerland), grants from Breast Cancer Now (London, UK) and the European Organisation for Research and Treatment of Cancer (Brussels, Belgium), and personal fees from Pfizer Inc. (New York, NY, USA) outside the submitted work. Jane Blazeby reports being a member of the National Institute for Health Research (NIHR) Clinical Trials Unit Standing Advisory Group (2015–19), the NIHR Health Technology Assessment (HTA) Surgery Themed Call Board (2012–13), the NIHR HTA Commissioning Board for Obesity (2011–12) and the NIHR HTA Strategy Committee (2009–12). Julia Brown reports being a member of the NIHR HTA Clinical Evaluation and Trials Funding Committee (2017 to present). Claire Hulme reports being a member of the NIHR HTA Commissioning Board (2013–17). Ann Henry reports grants from the NIHR Research for Patient Benefit programme (PB-PG-0816-10017: effective clinical cancer treatment, care and management of people with co-morbid cancer and dementia), Medical Research Council, Cancer Research UK (London, UK) and Royal College of Radiologists outside the submitted work. Kevin Franks reports personal fees and non-financial support from AstraZeneca plc (Cambridge, UK), personal fees from Roche Holding AG, Bristol Myers Squibb™ (New York, NY, USA) and Pfizer Inc., and non-financial support from Boerhinger Ingleheim (Ingelheim am Rhein, Germany) and Takeda Pharmaceutical Company Limited (Tokyo, Japan) outside the submitted work.